Lyra Therapeutics (LYRA) Assets (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Assets of $36.1 million in Q4 2025, down 17.39% on a QoQ basis from $43.7 million in Q3 2025, and down 45.58% YoY from $66.3 million in Q4 2024.
Lyra Therapeutics (LYRA) Assets (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Assets for 7 consecutive years, with $36.1 million the latest figure, recorded in Q4 2025.
- Assets for Q4 2025 came in at $36.1 million, down 45.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $36.1 million (down 45.58% YoY), and the FY2025 annual result was $36.1 million, down 45.58% from the prior year.
- Assets for Q4 2025 stood at $36.1 million, down from $43.7 million in the prior quarter.
- The five-year high for Assets was $142.6 million in Q4 2023, with the low at $36.1 million in Q4 2025.
- A 5-year average of $86.6 million and a median of $77.5 million in 2021 frame the typical range for Assets.
- Across the five-year window, Assets jumped 100.43% in 2022 and slumped 60.21% in 2025, its largest moves.
- Lyra Therapeutics' Assets stood at $54.9 million in 2021, then jumped by 100.43% to $110.0 million in 2022, then advanced by 29.67% to $142.6 million in 2023, then tumbled by 53.47% to $66.3 million in 2024, then sank by 45.58% to $36.1 million in 2025.
- The last three Assets figures came in at $36.1 million (Q4 2025), $43.7 million (Q3 2025), and $52.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 36.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.11 Mn |
| Sep 30, 2025 | 43.71 Mn |
| Jun 30, 2025 | 52.57 Mn |
| Mar 31, 2025 | 56.32 Mn |
| Dec 31, 2024 | 66.35 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 94.58 Mn |
| Mar 31, 2024 | 141.53 Mn |
| Dec 31, 2023 | 142.60 Mn |
| Sep 30, 2023 | 120.58 Mn |
| Jun 30, 2023 | 125.68 Mn |
| Mar 31, 2023 | 93.87 Mn |
| Dec 31, 2022 | 109.97 Mn |
| Sep 30, 2022 | 119.46 Mn |
| Jun 30, 2022 | 130.04 Mn |
| Mar 31, 2022 | 47.35 Mn |
| Dec 31, 2021 | 54.87 Mn |
| Sep 30, 2021 | 67.76 Mn |
| Jun 30, 2021 | 76.33 Mn |
| Mar 31, 2021 | 72.92 Mn |